Aurinia Pharmaceuticals Inc expected to post earnings of 2 cents a share - Earnings Preview

Aurinia Pharmaceuticals

29/10/2024 13:43

* Aurinia Pharmaceuticals Inc  AUPH.OQ   AUPH.O  is expected
to show a rise in quarterly revenue when it reports  results on
October 31 (estimated) for the period ending September 30 2024
    * The Victoria British Columbia-based  company is expected
to
report a 5.8% increase in revenue to $57.693 million from $54.52
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Aurinia Pharmaceuticals
Inc is
for earnings of 2 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is 10.00​, above​ its last closing price
of $7.24. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024              0.01       0.01      Met     20
 Mar. 31 2024  -0.18       -0.14      -0.03     Beat    78
 Dec. 31 2023              -0.16      -0.19     Missed  -16.3​
 Sep. 30 2023  -0.16       -0.17      -0.09     Beat    46.2
 ​​Jun.        -0.18       -0.18      -0.08     Beat    56.4
 30 2023                                                
 Jan. 1 0001   -0.22       -0.22      -0.18     Beat    18.7​
 Dec. 31 2022  -0.27       -0.27      -0.18     Beat    34
 Sep. 30 2022  -0.17       -0.17      -0.06     Beat    64.4
 This summary was machine generated October 29 at 13:43 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)